Ticker

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection with the appointment of Sandra Gurrola as VP Finance, Controller, the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option…

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell Engager Therapeutic Summit in San Diego, California. The Company presented data on its approach of simultaneously activating T-cells while inducing the expression of T-cell…

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026.

IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medicines, will participate in an investor webinar hosted by RedChip Companies (“RedChip”) on June 9, 2026, at 1:15pm PT. The exclusive event will feature Eric Poma, Ph.D.